Christopher James Frankenfield

Christopher James Frankenfield discloses dealings in Xilio Therapeutics, Inc. to SEC (Form 4). We count 4 filings; the first trade dates from 1 January 2025 and the latest from 2 January 2026.

Every open-market trade on record is a sale: 2 sales worth €10k. The rest of the record consists of 2 option exercises. Since January 2026: no purchases and 1 sale on the market.

Most recently, on 5 January 2026, the filings show an open-market sale worth €3,848 in Xilio Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.